论文部分内容阅读
近期,《Diabetes Care》发表了一项关于结构性检测(STEP)的研究报告,这项研究为期12个月,是前瞻性、随机分组的多中心临床试验。研究共纳人了483例来自美国34个基层医疗单位、血糖控制不佳(HbA_1c≥7.5%)、未使用胰岛素的2型糖尿病(T2DM)患者。将患者随机分成加强日常治疗的积极控制组(ACG组,n=227)和至少每季使用结构性自我血糖监测、加强日常治疗的结构性检测组(STG组,n=256)。STG组受试者使用Accu-Chek 3600 View血糖记录(罗氏诊断)。患者在每次回
Recently, Diabetes Care published a study on structural testing (STEP), a 12-month, prospective, randomized, multicenter trial. The study included 483 patients from 34 primary care units in the United States who had poor glycemic control (HbA_1c ≥7.5%) and type 2 diabetes (T2DM) without insulin. Patients were randomly assigned to a positive control group (ACG group, n = 227) for daily therapy and a structured test group for daily treatment (STG group, n = 256), using structured self-monitoring of blood glucose at least quarterly. Subjects in the STG group used Accu-Chek 3600 View blood glucose recordings (Roche Diagnostics). Patient at each time back